EP2019588A4 - Restauration de réponses visuelles par administration in vivo d'acides nucléiques de rhodopsine - Google Patents

Restauration de réponses visuelles par administration in vivo d'acides nucléiques de rhodopsine

Info

Publication number
EP2019588A4
EP2019588A4 EP07797340A EP07797340A EP2019588A4 EP 2019588 A4 EP2019588 A4 EP 2019588A4 EP 07797340 A EP07797340 A EP 07797340A EP 07797340 A EP07797340 A EP 07797340A EP 2019588 A4 EP2019588 A4 EP 2019588A4
Authority
EP
European Patent Office
Prior art keywords
recovery
nucleic acids
vivo administration
rhodopsin nucleic
visual reactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07797340A
Other languages
German (de)
English (en)
Other versions
EP2019588A2 (fr
Inventor
Zhuo-Hua Pan
Alexander M Dizhoor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Pennsylvania College of Optometry
Original Assignee
Wayne State University
Pennsylvania College of Optometry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Pennsylvania College of Optometry filed Critical Wayne State University
Priority to EP18176101.6A priority Critical patent/EP3437473A1/fr
Publication of EP2019588A2 publication Critical patent/EP2019588A2/fr
Publication of EP2019588A4 publication Critical patent/EP2019588A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP07797340A 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de rhodopsine Ceased EP2019588A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18176101.6A EP3437473A1 (fr) 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de la rhodopsine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79735706P 2006-05-04 2006-05-04
PCT/US2007/068263 WO2007131180A2 (fr) 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de rhodopsine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP18176101.6A Division EP3437473A1 (fr) 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de la rhodopsine

Publications (2)

Publication Number Publication Date
EP2019588A2 EP2019588A2 (fr) 2009-02-04
EP2019588A4 true EP2019588A4 (fr) 2010-11-24

Family

ID=38668588

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07797340A Ceased EP2019588A4 (fr) 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de rhodopsine
EP18176101.6A Withdrawn EP3437473A1 (fr) 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de la rhodopsine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18176101.6A Withdrawn EP3437473A1 (fr) 2006-05-04 2007-05-04 Restauration de réponses visuelles par administration in vivo d'acides nucléiques de la rhodopsine

Country Status (7)

Country Link
US (4) US8470790B2 (fr)
EP (2) EP2019588A4 (fr)
JP (5) JP2009536219A (fr)
CN (1) CN101484005A (fr)
AU (2) AU2007247929A1 (fr)
CA (1) CA2685900A1 (fr)
WO (1) WO2007131180A2 (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009022A2 (fr) 2002-07-18 2004-01-29 The General Hospital Corp. Methode permettant d'ameliorer la vision chez des personnes atteintes d'une degenerescence de la cellule photoreceptrice
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
EP1919497B1 (fr) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Canaux cationiques activees par la lumiere et leurs utilisations
CN101484005A (zh) * 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
WO2008086470A1 (fr) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University Système pour stimulation optique de cellules cibles
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
JP2008201692A (ja) * 2007-02-19 2008-09-04 Tohoku Univ 視覚機能の再生方法
WO2008106694A2 (fr) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systèmes, procédés et compositions pour stimulation optique de cellules cibles
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
MX2010011467A (es) * 2008-04-18 2011-02-15 Novartis Forschungsstiftung Novedosas herramientas y metodos terapeuticos para tratar la ceguera.
JP5801188B2 (ja) 2008-04-23 2015-10-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞を光刺激するためのシステム、方法、および組成物
WO2010011404A2 (fr) * 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vecteurs pour la délivrance de protéines photosensibles et procédés d’utilisation
MY152003A (en) 2008-05-29 2014-08-15 Univ Leland Stanford Junior Cell line, system and method for optical control of secondary messengers
MY162929A (en) 2008-06-17 2017-07-31 Univ Leland Stanford Junior Apparatus and methods for controlling cellular development
CA2728238C (fr) 2008-06-17 2019-03-12 M. Bret Schneider Procedes, systemes et dispositifs pour la stimulation optique de cellules cibles au moyen d'un element de transmission optique
CN102124109B (zh) * 2008-06-30 2013-10-16 Cho-A制药有限公司 猪α-S1-酪蛋白基因，其启动子及其用途
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
EP2465931B1 (fr) * 2009-08-10 2014-12-24 Tohoku University Rhodopsine canal photoréceptrice d'une efficacité d'expression améliorée
EP2483394A1 (fr) * 2009-09-29 2012-08-08 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Systèmes organotypiques fonctionnalisés
CN101693127B (zh) * 2009-09-30 2014-10-08 深圳先进技术研究院 皮肤材料及其制备方法
CN101812478B (zh) * 2009-12-29 2012-07-25 中国人民解放军第四军医大学 用于提高汉坦病毒融合蛋白g1s0.7表达的腺病毒高表达载体
EP2539015B1 (fr) * 2010-02-26 2015-12-30 Cornell University Prothèse de rétine
US9180309B2 (en) 2010-02-26 2015-11-10 Cornell University Retina prosthesis
EP2547762B1 (fr) 2010-03-17 2018-04-25 The Board of Trustees of the Leland Stanford Junior University Molécules laissant passer les ions sensibles à la lumière
US20130225664A1 (en) 2010-04-05 2013-08-29 Alan Horsager Methods and compositions for decreasing chronic pain
WO2011140279A1 (fr) * 2010-05-04 2011-11-10 Wayne State University Ciblage sous-cellulaire faisant intervenir aav de rhodopsines hétérologues dans des cellules ganglionnaires rétiniennes
CA2838330C (fr) 2010-08-23 2021-01-26 President And Fellows Of Harvard College Sondes optogenetiques pour mesurer le potentiel de membrane
US9207237B2 (en) 2010-08-23 2015-12-08 President And Fellows Of Harvard College Systems, methods, and workflows for optogenetics analysis
KR101945962B1 (ko) * 2010-09-08 2019-02-08 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 돌연변이 채널로돕신 2
US9302103B1 (en) 2010-09-10 2016-04-05 Cornell University Neurological prosthesis
WO2012051599A2 (fr) 2010-10-15 2012-04-19 Eos Neuroscience, Inc. Voies neurales à modulation
WO2012061679A2 (fr) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Opsines chimériques activées par la lumière et leurs procédés d'utilisation
WO2012061688A1 (fr) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Régulation optogénétique de comportements associés à la récompense
CA2816968C (fr) 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Dysfonctionnement du snc controle optiquement
US9522288B2 (en) 2010-11-05 2016-12-20 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
EP2635111B1 (fr) 2010-11-05 2018-05-23 The Board of Trustees of the Leland Stanford Junior University Protéines stabilisées de type opsine a fonction discontinue (ssfo) et leurs procédés d'utilisation
CA2816972C (fr) 2010-11-05 2019-12-03 The Board Of Trustees Of The Leland Stanford Junior University Controle et caracterisation de la fonction memoire
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US20120244174A1 (en) * 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
EP3029063B1 (fr) 2011-06-24 2019-10-16 Arctos Medical AG Protéine gpcr chimérique photosensible
US9155489B2 (en) 2011-07-05 2015-10-13 Deborah Zelinsky Devices for modulation of retinal stimulation and/or retinal signal processing and methods of use thereof
EP2736406B1 (fr) 2011-07-25 2019-09-04 NeuroNexus Technologies, Inc. Système pour la neuromodulation et pour la transfection comprenant des moyens pour la distribution active d'un liquide
US10493297B2 (en) 2011-07-25 2019-12-03 Neuronexus Technologies, Inc. Neuromodulation transfection system with passive fluid delivery
US9782091B2 (en) 2011-07-25 2017-10-10 Neuronexus Technologies, Inc. Opto-electrical device for artifact reduction
HK1199768A1 (en) 2011-08-25 2015-07-17 康奈尔大学 Retinal encoder for machine vision
US9192650B2 (en) 2011-08-30 2015-11-24 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis by eliciting the Faim2 antiapoptotic pathway
EP2776459A1 (fr) * 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Promoteur spécifique d'une cellule bâtonnet de la rétine
WO2013071231A1 (fr) * 2011-11-12 2013-05-16 Massachusetts Institute Of Technology Channelrhodopsines pour la commande optique de cellules
ES2724803T3 (es) 2011-12-16 2019-09-16 Univ Leland Stanford Junior Polipéptidos opsinas y métodos de utilización de los mismos
US8858929B2 (en) 2012-01-04 2014-10-14 Technion Research & Development Foundation Limited Optically sensitive cell network
CN104363961B (zh) 2012-02-21 2017-10-03 斯坦福大学托管董事会 用于治疗盆底神经源性病症的组合物和方法
CA2866405A1 (fr) 2012-03-05 2013-09-12 Wayne State University Identification de mutations de channelrhodopsine-2 (chop2) et procedes d'utilisation
WO2014033095A1 (fr) 2012-08-27 2014-03-06 Friedrich Miescher Institute For Biomedical Research Promoteur spécifique de circuits off de la rétine
EP2968476B1 (fr) * 2013-03-14 2021-05-05 Wayne State University Une plasmine pour l'utilisation pour améliorer l'administration de composés thérapeutiques aux yeux ou pour améliorer la vision
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
JP6594854B2 (ja) 2013-03-15 2019-10-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 行動状態の光遺伝学的制御方法
JP6549559B2 (ja) 2013-04-29 2019-07-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
EP3003391B1 (fr) 2013-05-31 2021-09-22 The Regents of The University of California Variants de virus adéno-associés et leurs méthodes d'utilisation
JP6621747B2 (ja) 2013-08-14 2019-12-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
JP6118239B2 (ja) 2013-11-29 2017-04-19 雅敏 堀 害虫の防除方法及び防除装置
US20170007720A1 (en) * 2014-02-21 2017-01-12 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
EP4678754A3 (fr) * 2014-03-11 2026-04-08 Wayne State University Promoteur mglur6 modifié et procédés d'utilisation
EP3800191B1 (fr) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions et procédés pour améliorer l'expression des gènes dans les cônes rétiniens
WO2015142984A1 (fr) 2014-03-18 2015-09-24 Washington University Procédés et compositions de substitution du chromophore décalée vers le rouge pour des applications optogénétiques
WO2015195769A2 (fr) 2014-06-18 2015-12-23 President And Fellows Of Harvard College Sondes optogénétiques pour mesurer un potentiel membranaire
WO2016115333A1 (fr) 2015-01-15 2016-07-21 President And Fellows Of Harvard College Sélection des cellules par voie optique
GB201503008D0 (en) * 2015-02-23 2015-04-08 Ucl Business Plc Treatment
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
US10519205B2 (en) 2015-03-19 2019-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods for use of anion channel rhodopsins
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ アデノ随伴ウイルス変異体及びその使用方法
KR102489987B1 (ko) 2015-04-20 2023-01-17 코넬 유니버시티 차원 데이터 축소를 이용하는 머신 비전
WO2016209654A1 (fr) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Procédés et dispositifs pour l'imagerie et/ou la commande optogénétique de neurones réagissant à la lumière
WO2017093566A1 (fr) * 2015-12-04 2017-06-08 Universite Pierre Et Marie Curie (Paris 6) Promoteurs et leurs utilisations
EP3210632B1 (fr) 2016-02-23 2022-09-28 EyeServ GmbH Thérapie génique pour le traitement d'une maladie de dégénérescence rétinienne
EP3426287A4 (fr) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Méthodes et kits destinés à être utilisés pour la prévention et le traitement de la candidose vulvo-vaginale
AU2017257169B2 (en) 2016-04-29 2021-07-08 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
WO2017187272A1 (fr) * 2016-04-29 2017-11-02 Gensight Biologics Sa Restauration visuelle optogénétique à l'aide de chrimson
US20170319669A1 (en) * 2016-05-03 2017-11-09 Wayne State University Method of enhancing viral-mediated gene delivery
US20190209708A1 (en) * 2016-05-17 2019-07-11 Friedrich Miescher Institute For Biomedical Research Novel therapeutic tools and methods for treating blindness
US11400311B2 (en) 2016-06-17 2022-08-02 Gensight Biologics Device for illuminating an object with a controlled light intensity and associated method
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP3504227A1 (fr) 2016-08-29 2019-07-03 Wayne State University Identification de mutations dans des variants de channelopsine ayant une sensibilité améliorée à la lumière et leurs procédés d'utilisation
EP4653537A3 (fr) * 2016-09-02 2026-01-07 Keio University Rhodopsin-gentherapie zur regeneration des sehvermögens oder zur verhinderung der abnahme des sehvermögens
CA3040179A1 (fr) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Capsides d'aav modifiees et leurs utilisations
RU2766353C2 (ru) * 2016-11-02 2022-03-15 Фридрих Мишер Инститьют Фор Байомедикал Рисерч Synp198, промотор для специфической экспрессии генов в ганглионарных клетках сетчатки, избирательных в отношении направления
JP6181278B1 (ja) 2016-12-22 2017-08-16 Ｊｉｇ−Ｓａｗ株式会社 可視光波長変換部を有する頭部装着型映像提示装置
WO2018134168A1 (fr) 2017-01-17 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'expression d'un polynucléotide d'intérêt dans les photorécepteurs à cônes
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
US20200115419A1 (en) * 2017-04-12 2020-04-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
CA3053154A1 (fr) 2017-06-30 2019-01-03 The Regents Of The University Of California Virions de virus adeno-associe a variants de capsides et methodes d'utilisation associees
JP2020534788A (ja) 2017-08-28 2020-12-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルスカプシド変異体及びその使用方法
CN111867635A (zh) 2017-10-20 2020-10-30 法国国家卫生及研究医学协会 包括视网膜下递送治疗有效量的重组aav9衍生载体的在对象的视锥细胞光感受器中表达目的多核苷酸的方法
SG11202005024QA (en) 2017-11-30 2020-06-29 Friedrich Miescher Institute For Biomedical Res Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium
US20190275169A1 (en) * 2018-03-07 2019-09-12 Circuit Therapeutics, Inc. Targeted immunosuppression for optogenetic intervention
JP7371083B2 (ja) * 2018-07-20 2023-10-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 遺伝子治療発現ベクターの眼内送達
JPWO2020054868A1 (ja) * 2018-09-14 2021-08-30 国立大学法人 名古屋工業大学 光応答性タンパク質及びその利用
WO2020148913A1 (fr) * 2019-01-18 2020-07-23 俊英 栗原 Prévention et inhibition de la progression de la maladie rétinienne, amélioration de la fonction comportementale cognitive visuelle et renforcement de la fonction visuelle
WO2020201828A1 (fr) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anticorps anti-tauc3 et leurs utilisations
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
EP3733139A1 (fr) 2019-05-02 2020-11-04 Gensight Biologics Appareil et procédé de visualisation pour la projection d'un signal lumineux
CN110521842A (zh) * 2019-05-06 2019-12-03 高思 人眼晶状体和视网膜感光细胞营养素裹养眼明目草药糖果
WO2021049634A1 (fr) 2019-09-13 2021-03-18 株式会社レストアビジョン Construction d'acides nucléiques codant pour la rhodopsine chimère
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
AU2020385387A1 (en) * 2019-11-22 2022-06-02 Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico Materials and methods for treatment of disorders associated with the IGHMBP2 gene
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
WO2021165876A1 (fr) * 2020-02-19 2021-08-26 Friedrich Miescher Institute For Biomedical Research Nouveaux outils thérapeutiques et procédés utilisant des récepteurs sensibles à la température permettant le traitement de la cécité
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4119666A4 (fr) * 2020-03-13 2024-04-03 Nagoya Institute Of Technology Protéine sensible à la lumière pour la reconnaissance de couleur et son utilisation
CA3179895A1 (fr) 2020-04-24 2021-10-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procedes d'inhibition de l'induction de reponses immunitaires a des cellules transduites exprimant un produit transgenique apres therapie genique oculaire
AU2022299552A1 (en) * 2021-06-25 2024-01-04 Oxford Biomedica (Us) Llc Adeno-associated virus packaging systems
KR20260015799A (ko) 2023-05-04 2026-02-03 젠사이트 바이올로직스 관찰 장치
EP4704972A1 (fr) 2023-05-04 2026-03-11 Gensight Biologics Procédé de commande de l'éclairage d'une surface d'un objet par une unité de projection et procédé et dispositifs associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202398A1 (en) * 2002-04-11 2005-09-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of biological photoreceptors as directly light-activated ion channels
WO2007024391A2 (fr) * 2005-07-22 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Canaux cationiques activees par la lumiere et leurs utilisations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) * 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) * 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
IT237434Y1 (it) 1997-04-17 2000-09-13 Philco Italiana Lavatrice con carrello per il suo spostamento
EP0977880A2 (fr) 1997-04-21 2000-02-09 University Of Florida Produits agissant contre des affections retiniennes et traitement correspondant
CA2346262A1 (fr) 1998-09-17 2000-03-23 University Of Florida Methodes de traitement de maladies degeneratives de la retine
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
WO2002082904A2 (fr) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Traitement soignant ou retardant l'installation de la cecite
AU2002323210A1 (en) * 2001-08-16 2003-03-03 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
WO2004009022A2 (fr) * 2002-07-18 2004-01-29 The General Hospital Corp. Methode permettant d'ameliorer la vision chez des personnes atteintes d'une degenerescence de la cellule photoreceptrice
US7321796B2 (en) 2003-05-01 2008-01-22 California Institute Of Technology Method and system for training a visual prosthesis
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7427138B2 (en) * 2003-11-05 2008-09-23 Neurovision, Inc. Method and apparatus for improving visual perception
WO2005123183A2 (fr) 2004-06-11 2005-12-29 University Of South Florida Dispositif d'electroporation et procede d'introduction d'adn dans les tissus oculaires
CN101484005A (zh) * 2006-05-04 2009-07-15 韦恩州立大学 通过向体内递送视紫红质核酸恢复视觉响应
WO2011140279A1 (fr) 2010-05-04 2011-11-10 Wayne State University Ciblage sous-cellulaire faisant intervenir aav de rhodopsines hétérologues dans des cellules ganglionnaires rétiniennes
KR101945962B1 (ko) 2010-09-08 2019-02-08 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 돌연변이 채널로돕신 2
CA2866405A1 (fr) 2012-03-05 2013-09-12 Wayne State University Identification de mutations de channelrhodopsine-2 (chop2) et procedes d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202398A1 (en) * 2002-04-11 2005-09-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of biological photoreceptors as directly light-activated ion channels
WO2007024391A2 (fr) * 2005-07-22 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Canaux cationiques activees par la lumiere et leurs utilisations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FLANNERY J G ET AL: "Looking within for vision", NEURON, CELL PRESS, US LNKD- DOI:10.1016/J.NEURON.2006.03.027, vol. 50, no. 1, 6 April 2006 (2006-04-06), pages 1 - 3, XP002406403, ISSN: 0896-6273 *
HAN XUE ET AL: "Multiple-color optical activation, silencing, and desynchronization of neural activity, with single-spike temporal resolution.", PLOS ONE 2007 LNKD- PUBMED:17375185, vol. 2, no. 3, 2007, pages e299, XP002487912, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0000299 *
INNA REUTSKY ET AL: "Patterned optical activation of Channelrhodopsin II expressing retinal ganglion cells", NEURAL ENGINEERING, 2007. CNE '07. 3RD INTERNATIONAL IEEE/EMBS CONFERENCE ON, IEEE, PISCATAWAY, NJ, USA, 1 May 2007 (2007-05-01), pages 50 - 52, XP031174677, ISBN: 978-1-4244-0791-0 *
NAGEL G ET AL: "Channelrhodopsin-2, a directly light-gated cation-selective membrane channel", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.1936192100, vol. 100, no. 24, 25 November 2003 (2003-11-25), pages 13940 - 13945, XP002406405, ISSN: 0027-8424 *
PAN Z-H ET AL: "Functional expression of a directly light-gated membrane channel in mammalian retinal neurons: A potential strategy for restoring light sensitivity to the retina after photoreceptor degeneration", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE,, 1 May 2005 (2005-05-01), XP009113473 *
See also references of WO2007131180A2 *

Also Published As

Publication number Publication date
WO2007131180A2 (fr) 2007-11-15
US20140121265A1 (en) 2014-05-01
EP2019588A2 (fr) 2009-02-04
CN101484005A (zh) 2009-07-15
JP2016121190A (ja) 2016-07-07
AU2007247929A1 (en) 2007-11-15
JP2009536219A (ja) 2009-10-08
US11883463B2 (en) 2024-01-30
AU2013257450B2 (en) 2016-08-25
US20210100875A1 (en) 2021-04-08
CA2685900A1 (fr) 2007-11-15
US9730981B2 (en) 2017-08-15
US20180214513A1 (en) 2018-08-02
JP2020203924A (ja) 2020-12-24
WO2007131180A3 (fr) 2008-07-31
EP3437473A1 (fr) 2019-02-06
JP2014040469A (ja) 2014-03-06
US20100015095A1 (en) 2010-01-21
JP2018076377A (ja) 2018-05-17
US8470790B2 (en) 2013-06-25

Similar Documents

Publication Publication Date Title
EP2019588A4 (fr) Restauration de réponses visuelles par administration in vivo d'acides nucléiques de rhodopsine
EP2124974A4 (fr) Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
AU2013257450A1 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
GB2444794B (en) Electrophoresis display and driving method thereof
EP1979472A4 (fr) Determination metabolique dans une technologie de procreation medicalement assistee
EP2207899A4 (fr) Assemblage d'acides nucléiques de grande taille
DK2094086T3 (da) Indgivelse in vivo af dobbeltstrenget rna til en målcelle
IL190728A0 (en) Intravenous essential fatty acid emulsion
EP2178613A4 (fr) Recuperation des nappes de decantation des residus
IL204037A (en) Saccharide-containing protein conjugates and uses thereof
DK2068822T4 (da) Selvpræserverede vandige farmaceutiske sammensætninger
ATE538221T1 (de) Chloridhaufenlaugung
EP2066686A4 (fr) Compositions stabilisantes et procédés permettant d'extraire un acide ribonucléique
EP2027281A4 (fr) Production de n-glycanes sialylés dans des eucaryotes inférieurs
BRPI1010307A2 (pt) composições e métodos relacionados à variantes de proteína a (spa).
DK1984502T3 (da) Nukleinsyre
EP2515914A4 (fr) Bioconjugaison de la tyrosine par des réactions de type ène en milieu aqueux
ATE501435T1 (de) Authentifizierung einnehmbarer produkte mit sacchariden als marker
ATE422159T1 (de) Medikamenten-filmstreifen zum hinweis von überdosierung
EP2300038A4 (fr) Médaiteurs peptidiques améliorés d'efflux de cholestérol
IL193411A0 (en) Methods of extracting nucleic acids
ZA201001178B (en) Improvements in or relating to frangible posts
EP1838856A4 (fr) Procédé de délivrance d'acides nucléiques aux neurones périphériques
ATE522201T1 (de) Nukleinsäurekomplex und nukleinsäure-abgabe- zusammensetzung
EP2121921A4 (fr) Nouveaux gènes et molécules d'arn qui confèrent une tolérance à la contrainte

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20101027

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/00 20060101ALI20101021BHEP

Ipc: C07K 14/705 20060101ALI20101021BHEP

Ipc: A01N 43/04 20060101AFI20081204BHEP

17Q First examination report despatched

Effective date: 20110805

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20180305